These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38587249)

  • 1. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    Bergmark BA; Marston NA; Prohaska TA; Alexander VJ; Zimerman A; Moura FA; Murphy SA; Goodrich EL; Zhang S; Gaudet D; Karwatowska-Prokopczuk E; Tsimikas S; Giugliano RP; Sabatine MS;
    N Engl J Med; 2024 May; 390(19):1770-1780. PubMed ID: 38587249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
    Stroes ESG; Alexander VJ; Karwatowska-Prokopczuk E; Hegele RA; Arca M; Ballantyne CM; Soran H; Prohaska TA; Xia S; Ginsberg HN; Witztum JL; Tsimikas S;
    N Engl J Med; 2024 May; 390(19):1781-1792. PubMed ID: 38587247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
    Gaudet D; Alexander VJ; Baker BF; Brisson D; Tremblay K; Singleton W; Geary RS; Hughes SG; Viney NJ; Graham MJ; Crooke RM; Witztum JL; Brunzell JD; Kastelein JJ
    N Engl J Med; 2015 Jul; 373(5):438-47. PubMed ID: 26222559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
    Gaudet D; Pall D; Watts GF; Nicholls SJ; Rosenson RS; Modesto K; San Martin J; Hellawell J; Ballantyne CM
    JAMA Cardiol; 2024 Jul; 9(7):620-630. PubMed ID: 38583092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
    Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D
    Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
    Ballantyne CM; Vasas S; Azizad M; Clifton P; Rosenson RS; Chang T; Melquist S; Zhou R; Mushin M; Leeper NJ; Hellawell J; Gaudet D
    N Engl J Med; 2024 Sep; 391(10):899-912. PubMed ID: 38804517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans.
    Karwatowska-Prokopczuk E; Lesogor A; Yan JH; Hoenlinger A; Margolskee A; Li L; Tsimikas S
    Lipids Health Dis; 2024 Oct; 23(1):329. PubMed ID: 39363329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
    N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
    Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
    Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olezarsen, a liver-directed
    Hooper AJ; Bell DA; Burnett JR
    Expert Opin Pharmacother; 2024 Oct; 25(14):1861-1866. PubMed ID: 39305266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2011 Jul; 108(1):40-6. PubMed ID: 21565322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
    Rosenson RS; Gaudet D; Hegele RA; Ballantyne CM; Nicholls SJ; Lucas KJ; San Martin J; Zhou R; Muhsin M; Chang T; Hellawell J; Watts GF;
    N Engl J Med; 2024 Sep; 391(10):913-925. PubMed ID: 38809174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
    Karwatowska-Prokopczuk E; Tardif JC; Gaudet D; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Amour ES; Alexander VJ; Xia S; Otvos JD; Witztum JL; Tsimikas S;
    J Clin Lipidol; 2022; 16(5):617-625. PubMed ID: 35902351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.
    Gaudet D; Clifton P; Sullivan D; Baker J; Schwabe C; Thackwray S; Scott R; Hamilton J; Given B; Melquist S; Zhou R; Chang T; San Martin J; Watts GF; Goldberg IJ; Knowles JW; Hegele RA; Ballantyne CM
    NEJM Evid; 2023 Dec; 2(12):EVIDoa2200325. PubMed ID: 38320498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.